The Healthcare Champion of the Year, to be selected by J&J and a panel of industry experts, will be recognized at Time’s “A Year in TIME” celebration in December.

Widespread misconceptions about Type 1 diabetes could be contributing to a reluctance to get screened for the autoimmune disease, according to a survey Sanofi commissioned.

On paper, it was another strong quarter for Carvykti. Johnson & Johnson reported record sales for the CAR-T therapy, signaling robust demand in multiple myeloma. Yet record revenue wasn’t enough to spare its partner, Legend Biotech, from a 10% stock drop, thanks in part to comments made during J&J’s earnings […]

South Korean contract manufacturer Samsung Biologics has tapped into the booming peptide production and weight loss market with plans to buy out Switzerland-based CDMO PolyPeptide for 1.46 billion Swiss francs ($1.8 billion).

The FDA has converted its accelerated approval for Novartis’ Fabhalta into a full blessing to treat patients with immunoglobulin A nephropathy (IgAN). The drug is endorsed to slow kidney function decline in adults at risk of disease progression.

From Indiana to Iceland, the FDA this week disclosed concerns raised during recent visits to a pair of manufacturing sites with troubled regulatory histories.